Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1070 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2024-12-05 (stocktitan.net)
Charles River Labs Launches Game-Changing Biotech Incubator Program for Early-Stage Companies | CRL Stock News
Charles River Laboratories unveils innovative incubator program offering early-stage biotech companies comprehensive support in therapy development and regulatory expertise.
Read more
2022-12-02 (aithority.com)
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
Charles River Laboratories International, launches the Endosafe Nexus 200, expanding its robust endotoxin testing portfolio
Read more
2010-05-21 (levinassociates.com)
The Health Care M&A Monthly: Charles River Expands In China- Levin Associates
Pays $1.6 Billion For WuXi PharmaTech True to its name, Charles River Laboratories International (NYSE: CRL) is expanding its overseas operations with the $1.6 billion acquisition of WuXi PharmaTech (NYSE: WX).
Read more
2008-01-02 (outsourcing-pharma.com)
New China:US preclinical partnership formed
US-based MPI Research and China's Shanghai Medicilon have formed a joint venture in preclinical services, as they position themselves to cash in on what is a budding market sector in China.
Read more
(drugtargetreview.com)
Charles River Laboratories announces new tumour model compendium
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.
Read more
(morningstar.com)
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids
Cell and gene therapies often rely on plasmid DNA (pDNA) as a critical starting material. However, production challenges such as capacity bottlenecks and timeline pressures, as well as a need for process development optimization can result in increased lead time, cost and complexity. Charles River’
Read more